Geron

Geron Equity

The The Equity of Geron (GERN) as of Oct 9, 2026 is 225.87 M USD. In the previous year, The Equity was 280.32 M USD — a change of -19.42% (lower).

Equity

225.87 MUSD

YoY

-19.42%

Last updated:

In 2025, Geron's equity was 225.87 M USD, a -19.42% increase from the 280.32 M USD equity in the previous year.

The Geron Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
177.73 M USD
Jan 1, 2019
135.16 M USD
Jan 1, 2020
210.95 M USD
Jan 1, 2021
126.42 M USD
Jan 1, 2022
80.00 M USD
Jan 1, 2023
247.95 M USD
Jan 1, 2024
280.32 M USD
Jan 1, 2025
225.87 M USD
The Geron Equity history
YEAREquityYoY
225.87 MUSD-19.42%
280.32 MUSD+13.06%
247.95 MUSD+209.94%
80.00 MUSD-36.72%
126.42 MUSD-40.07%
210.95 MUSD+56.08%
135.16 MUSD-23.96%
177.73 MUSD+71.23%
103.80 MUSD-15.18%
122.38 MUSD-13.89%
142.13 MUSD+8.73%
130.71 MUSD—
Access this data via the Eulerpool API

Geron Stock analysis

What does Geron do? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Geron's Equity

Geron's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Geron's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Geron's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Geron's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Geron’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Geron stock

The Equity of Geron is 225.87 M USD in 2025.

The Equity of Geron changed from 280.32 M USD to 225.87 M USD, representing a -19.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Geron since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Geron historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Geron

All Key Metrics — Geron